The COVID-19 pandemic disrupted routine oncology care, including GIST screenings and follow-ups, leading to a post-pandemic surge in delayed diagnoses. Patients with undetected or untreated GISTs now present with larger, more aggressive tumors, increasing demand for intensive treatments like emergency surgeries and high-dose TKI therapies. This trend, while challenging, highlights the market’s resilience and the urgent need for sustained screening efforts, making post-pandemic recovery a key focus for industry stakeholders.

Screening delays had dire consequences. Between 2020 and 2022, global GIST screenings dropped by 35%, with late-stage diagnoses rising by 22% during this period. A 2023 report by the International Rare Cancer Initiative found that delayed cases had a 30% higher recurrence risk, correlating with a 15% increase in TKI-resistant tumors. In response, healthcare systems are ramping up catch-up programs; the EU allocated €40 million in 2023 to fund GIST screenings, aiming to screen 90% of high-risk patients by 2025.

This surge has boosted treatment demand. Emergency surgery cases grew by 40% in 2023, while TKI drug sales rose by 30%, driven by patients requiring immediate intervention. Clinics in Italy and Spain reported a 50% rise in regorafenib prescriptions, as delayed cases often involve TKI-resistant mutations. Meanwhile, demand for supportive care—like anti-nausea medications and nutritional supplements—increased by 25%, addressing side effects from aggressive treatments.

The post-pandemic momentum is expected to persist. As screening rates recover, early-stage diagnoses will rise, but the backlog of delayed cases will keep advanced therapy demand elevated. By 2025, therapy spending is projected to reach $1.8 billion, up from $1.2 billion in 2023. For businesses, understanding post-pandemic trends GIST care reveals demand spikes and patient needs, guiding investment in both diagnostics and therapies.